Compare iShares Gold Trust (IAU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Gold Trust trades at $77.69, while State Street SPDR S&P Biotech ETF trades at $151.85. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals.
| IAU | XBI | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Broad Market / Factor |
52-Week High | $101.57 | $164.28 |
52-Week Low | $61.62 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU, the iShares Gold Trust ETF, trades at $75.35, down 0.2% with a bearish technical signal from moving averages. The ETF tracks physical gold prices, which have shown volatility amid Middle East tensions and shifting Fed rate expectations. Recent institutional activity includes Eurizon Asset Management acquiring 482,015 shares in Q1 2026 while AlTi Global reduced its position by 1.3%.
Gold's outlook balances strong central bank demand against interest rate pressures. The risk/reward appears favorable with limited downside, though Fed policy remains the primary driver. Physical gold demand from Asian markets provides support, but higher rates could continue to cap near-term gains.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
